title: Evaluating Chemotherapy at the End of Life--Reply.
authors.affiliation: Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York2Division of Geriatrics and Palliative Medicine, Department of Medicine, Weill Cornell Medical College, New York, New York.
authors.forename: Holly G
authors.initials: HG
authors.lastname: Prigerson
authors.affiliation: Herbert Irving Comprehensive Cancer Center, Department of Medicine, College of Physicians and Surgeon, New York, New York4Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
authors.forename: Alfred I
authors.initials: AI
authors.lastname: Neugut
authors.affiliation: Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York5Department of Radiology, Weill Cornell Medical College, New York, New York.
authors.forename: Paul K
authors.initials: PK
authors.lastname: Maciejewski
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006304:Health Status; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013727:Terminal Care / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents